AB0978 EFFICACY OF ANAKINRA TREATMENT IN PEDIATRIC RHEUMATIC DISEASES; A SINGLE-CENTER EXPERIENCE

Background:

Anakinra, a recombinant IL-1 receptorantagonist, is a treatment option that acts byblocking the biological activity of IL-1 in autoinflammatory conditions. The diseases that the IL-1 was over expressed are the potential conditions for this treatment. Such as familial Mediterranean fever (FMF), cryopyrin-associated periodic syndrome (CAPS), and hyperimmunglobulin D syndrome (HIDS) with monogenic inheritance, and systemic juvenile idiopathic arthritis (SoJIA) or idiopathic recurrent pericarditis as non-Mendelian polygenic diseases, can be listed as examples of these diseases.

Objectives:

The aim of this study was to review the efficacy of anakinra treatment in children with rheumatic disease followed in our center.

Methods:

The study group consisted of children with pediatric rheumatic diseases followed up in the Pediatric Rheumatology Department of University of Health Sciences and treated with anakinra (anti-IL 1) for at least one month, between 1 July 2016 and 1 January 2020. The data of these patients were collected retrospectively. The disease activity of the patients at 3rd month and 12th month after the treatment were assessed. We aim to report our experiences of pediatric rheumatic diseases treated with anakinra.

Results:

There were 28 patients treated with anakinra for the different pediatric rheumatic diseases. The diagnoses of these patients were as follows; eight were macrophage activation syndrome (MAS) complicating SoJIA, six were HIDS, four were CAPS, four were FMF, four were idiopathic recurrent pericarditis, one was deficiency of interleukin-36 receptor antagonist (DITRA), and one was undefined systemic autoinflammatory disease. 46.4% of the patients were male and 53.6% were female. The median age of diagnosis of the patients was 6.5 ((interquartile range (IQR): 4-12.7) years. The median follow-up duration of the patients was 14 (IQR: 3.7-28) months. The patients median anakinra treatment duration was 3 (IQR: 1-4) months. Fever reduced and C-reactive protein normalized within median 2 (IQR: 1-3) and 5 (IQR: 5-7) days, respectively. In the 3rd month after treatment; It was observed that 53.6% of patients achieved a complete remission (no attack was seen or MAS was improved). The frequency of attacks were decreased more than 50% in 35.7% of patients and less than 50% in 7.1%. 3.6% of patients were unresponsive to treatment. In the 12th month assessment after the initiation of treatment, it was observed that 28.6% of patients were still under anakinra treatment and in remission, 10.7% of them were in remission without anakinra treatment. In 60.7% of patients, anakinra was switch to other biological treatments for different reasons (35.7% partial response or unresponsiveness, 17.8% injection site reactions and 7.1% daily-injection difficulty). Biologic drug switch to canakinumab and tocilizumab was observed in 88.2% and 11.8% of patients, respectively. One patient developed recurrent MAS episodes when the anakinra dose was tapered, and one another patient was unresponsive to the anakinra and dead due to secondary to MAS.

Conclusion:

Anakinra seems to be a successful treatment to achieve inactive disease in a significant portion of patients in the early period. The recurrence of disease attacks while drug tapering and injection site reactions were appears the main causes of treatment switch or discontinuation.

References:

[1]Ben-Zvi I, Kukuy O, Giat E, Pras E, Feld O, Kivity Set al. Anakinra for Colchicine-Resistant Familial Mediterranean Fever: A Randomized, Double-Blind, Placebo-Controlled Trial. Arthritis Rheumatol. 2017;69:854-862.

Acknowledgments:

We thank our patients and their families

Disclosure of Interests:

None declared

Hedonic hunger, food addiction, and night eating syndrome triangle in adolescents and ıts relationship with body mass ındex

BACKGROUND

The relationship between adolescent obesity and eating disorders is an issue that needs urgent attention. Screening for eating disorders is as important as dietary interventions to treat obesity. This study aimed to determine the relationship between hedonic hunger, food addiction, and night eating syndrome, which are considered potential risk factors for obesity, and body mass index (BMI) in adolescents.

METHODS

The data were collected through an online questionnaire. The "Power of Food Scale (PFS)" was used to assess hedonic hunger; the "Yale Food Addiction Scale for Children 2.0 (dYFAS-C 2.0)" was used to assess food addiction; and the "Night Eating Questionnaire (NEQ)" was used to assess night eating syndrome (NES)". BMI was calculated using self-reported height and weight values of adolescents. The mediated structural model analysis was performed to evaluate the effect of hedonic hunger on BMI z score via food addiction and NES.

RESULTS

The study was conducted with 614 voluntary adolescents aged between 11 and 18 years. The dYFAS-C 2.0 and NEQ scores were found to be higher in adolescents with overweight and obesity, and the BMI z-score of the adolescents had significant positive correlation with their PFS scores (p < .001). Hedonic hunger has no direct effect on BMI independent of food addiction and NES (β = - 0.051, p = .468), but when the total indirect effect is evaluated with the bootstrap analysis, it was found that one-unit increase in hedonic hunger score increases BMI z-score by approximately 0.22 units (β = 0.223, SE = 0.046, 95% CI 0.131-0.313). Hedonic hunger, food addiction, and NES together explained 5.2% of the total variance in BMI z score.

CONCLUSION

This study showed that hedonic hunger significantly predicted BMI z-score in adolescents through food addiction and NES. This emphasizes the critical importance of evaluating adolescents in terms of hedonic hunger, food addiction, and NES in the prevention, diagnosis, and treatment of obesity.